Registered trade mark on medicaments supports patent or proprietary classification; export clearances under bond qualify for credit benefit.

Medicaments bearing the assessee's registered trade mark were treated as patent or proprietary medicaments under Chapter 30, because the chapter note covers preparations bearing a brand name or registered trade mark and the goods were not shown to fall within the relevant pharmacopoeial descriptions. The contrary classification under sub-heading 3003.20 was rejected. Exported goods cleared under bond were also held eligible for Modvat/Cenvat credit, as the export clearance procedure supported credit entitlement. The appellate challenge therefore failed, with both the classification adopted by the Commissioner (Appeals) and the export-linked credit benefit being upheld.

---

---

Issues: (i) whether medicaments affixed with the assessee's registered trade mark were classifiable under sub-heading 3003.10 as patent or proprietary medicaments rather than under sub-heading 3003.20; (ii) whether exported goods cleared under bond were eligible for Modvat/Cenvat credit.

Issue (i): whether medicaments affixed with the assessee's registered trade mark were classifiable under sub-heading 3003.10 as patent or proprietary medicaments rather than under sub-heading 3003.20.

Analysis: The applicable chapter note treats as patent or proprietary medicaments those preparations which bear a brand name or registered trade mark. The goods were not shown to fall within the pharmacopoeia or other publications referred to in the chapter note, and the trade mark affixed on the containers was a registered trade mark of the assessee. The precedent relied on by the Revenue was distinguished because it dealt with a mere house mark and not with a registered trade mark used on the goods.

Conclusion: The goods were correctly classified under sub-heading 3003.10, and the contrary classification under sub-heading 3003.20 was rejected.

Issue (ii): whether exported goods cleared under bond were eligible for Modvat/Cenvat credit.

Analysis: The goods were exported and the clearance was under the prescribed export procedure. On that basis, the rules governing export clearances and credit entitlement supported the assessee's eligibility for the credit benefit.

Conclusion: The assessee was entitled to the credit benefit in respect of the exported goods.

Final Conclusion: The appellate challenge failed because the classification adopted by the Commissioner (Appeals) was upheld and the assessee's entitlement to credit in respect of export clearances was affirmed.

Ratio Decidendi: For Chapter 30, a medicament bearing a registered trade mark or brand name, and not covered by the pharmacopoeial description in the chapter note, is to be treated as a patent or proprietary medicament; a mere house mark does not yield the same result.

---